KLP Kapitalforvaltning AS Makes New $12.32 Million Investment in IQVIA Holdings Inc. (NYSE:IQV)

KLP Kapitalforvaltning AS purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 62,675 shares of the medical research company’s stock, valued at approximately $12,316,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Synergy Asset Management LLC purchased a new position in shares of IQVIA during the 4th quarter worth $33,000. Avior Wealth Management LLC boosted its stake in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares during the last quarter. Lee Danner & Bass Inc. purchased a new position in shares of IQVIA during the 4th quarter worth $44,000. Versant Capital Management Inc boosted its stake in shares of IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in shares of IQVIA during the 4th quarter worth $60,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IQV. Barclays lowered their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Morgan Stanley lifted their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Robert W. Baird lowered their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Finally, JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Stock Performance

IQVIA stock opened at $185.85 on Monday. The company’s 50-day moving average price is $194.94 and its 200-day moving average price is $208.16. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $254.54. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market cap of $32.77 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.